Fast Market Research

New Market Study Published: Biolink Group as - Product Pipeline Review - 2012

Recently published research from Global Markets Direct, "Biolink Group AS - Product Pipeline Review - 2012", is now available at Fast Market Research


Boston, MA -- (SBWIRE) -- 11/28/2012 -- Global Market Direct's pharmaceuticals report, "Biolink Group AS - Product Pipeline Review - 2012" provides data on the Biolink Group AS's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Biolink Group AS's corporate website, SEC filings, investor presentations and featured press releases, both from Biolink Group AS and industry-specific third party sources, put together by Global Markets Direct's team.


- Biolink Group AS - Brief Biolink Group AS overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Biolink Group AS human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Biolink Group AS with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Biolink Group AS's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

View Full Report Details and Table of Contents

Reasons to Get this Report

- Evaluate Biolink Group AS's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Biolink Group AS in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Biolink Group AS's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Biolink Group AS.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Biolink Group AS and identify potential opportunities in those areas.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Ark Therapeutics Group plc - Product Pipeline Review - 2012
- Proximagen Group plc - Product Pipeline Review - 2012
- Simcere Pharmaceutical Group - Product Pipeline Review - 2012
- Pharming Group N.V. - Product Pipeline Review - 2012
- ProStrakan Group plc - Product Pipeline Review - 2012
- Angelini Group - Product Pipeline Review - 2012
- Phynova Group Ltd - Product Pipeline Review - 2012
- Patrys Limited - Product Pipeline Review - 2012
- Small-Cell Lung Cancer - Pipeline Review, H1 2012
- Sarcomas - Pipeline Review, H1 2012